S&P 500   3,919.27 (-4.15%)
DOW   31,455.04 (-3.67%)
QQQ   291.15 (-4.91%)
AAPL   140.32 (-5.98%)
MSFT   254.13 (-4.76%)
FB   193.56 (-4.47%)
GOOGL   2,251.17 (-3.36%)
AMZN   2,140.67 (-7.22%)
TSLA   708.10 (-7.03%)
NVDA   169.54 (-6.73%)
BABA   87.40 (-4.99%)
NIO   15.76 (-5.23%)
AMD   96.44 (-5.88%)
CGC   5.61 (-4.75%)
MU   70.86 (-4.86%)
T   20.20 (-1.80%)
GE   75.06 (-1.75%)
F   12.79 (-5.47%)
DIS   104.65 (-3.67%)
AMC   12.80 (-0.78%)
PFE   50.28 (-2.06%)
PYPL   77.10 (-3.32%)
NFLX   178.04 (-6.57%)
S&P 500   3,919.27 (-4.15%)
DOW   31,455.04 (-3.67%)
QQQ   291.15 (-4.91%)
AAPL   140.32 (-5.98%)
MSFT   254.13 (-4.76%)
FB   193.56 (-4.47%)
GOOGL   2,251.17 (-3.36%)
AMZN   2,140.67 (-7.22%)
TSLA   708.10 (-7.03%)
NVDA   169.54 (-6.73%)
BABA   87.40 (-4.99%)
NIO   15.76 (-5.23%)
AMD   96.44 (-5.88%)
CGC   5.61 (-4.75%)
MU   70.86 (-4.86%)
T   20.20 (-1.80%)
GE   75.06 (-1.75%)
F   12.79 (-5.47%)
DIS   104.65 (-3.67%)
AMC   12.80 (-0.78%)
PFE   50.28 (-2.06%)
PYPL   77.10 (-3.32%)
NFLX   178.04 (-6.57%)
S&P 500   3,919.27 (-4.15%)
DOW   31,455.04 (-3.67%)
QQQ   291.15 (-4.91%)
AAPL   140.32 (-5.98%)
MSFT   254.13 (-4.76%)
FB   193.56 (-4.47%)
GOOGL   2,251.17 (-3.36%)
AMZN   2,140.67 (-7.22%)
TSLA   708.10 (-7.03%)
NVDA   169.54 (-6.73%)
BABA   87.40 (-4.99%)
NIO   15.76 (-5.23%)
AMD   96.44 (-5.88%)
CGC   5.61 (-4.75%)
MU   70.86 (-4.86%)
T   20.20 (-1.80%)
GE   75.06 (-1.75%)
F   12.79 (-5.47%)
DIS   104.65 (-3.67%)
AMC   12.80 (-0.78%)
PFE   50.28 (-2.06%)
PYPL   77.10 (-3.32%)
NFLX   178.04 (-6.57%)
S&P 500   3,919.27 (-4.15%)
DOW   31,455.04 (-3.67%)
QQQ   291.15 (-4.91%)
AAPL   140.32 (-5.98%)
MSFT   254.13 (-4.76%)
FB   193.56 (-4.47%)
GOOGL   2,251.17 (-3.36%)
AMZN   2,140.67 (-7.22%)
TSLA   708.10 (-7.03%)
NVDA   169.54 (-6.73%)
BABA   87.40 (-4.99%)
NIO   15.76 (-5.23%)
AMD   96.44 (-5.88%)
CGC   5.61 (-4.75%)
MU   70.86 (-4.86%)
T   20.20 (-1.80%)
GE   75.06 (-1.75%)
F   12.79 (-5.47%)
DIS   104.65 (-3.67%)
AMC   12.80 (-0.78%)
PFE   50.28 (-2.06%)
PYPL   77.10 (-3.32%)
NFLX   178.04 (-6.57%)
NASDAQ:COCP

Cocrystal Pharma (COCP) Stock Forecast, Price & News

$0.39
0.00 (-0.05%)
(As of 05/18/2022 01:13 PM ET)
Add
Compare
Today's Range
$0.39
$0.39
50-Day Range
$0.38
$0.59
52-Week Range
$0.37
$1.49
Volume
16 shs
Average Volume
275,927 shs
Market Capitalization
$37.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.13
30 days | 90 days | 365 days | Advanced Chart
Receive COCP News and Ratings via Email

Sign-up to receive the latest news and ratings for Cocrystal Pharma and its competitors with MarketBeat's FREE daily newsletter.

Cocrystal Pharma logo

About Cocrystal Pharma

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.

Headlines

Cocrystal Pharma GAAP EPS of -$0.04 in-line
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:COCP
Fax
N/A
Employees
13
Year Founded
N/A

Sales & Book Value

Annual Sales
$2.01 million
Book Value
$0.80 per share

Profitability

Net Income
$-14.19 million
Pretax Margin
-2,351.57%

Debt

Price-To-Earnings

Miscellaneous

Free Float
92,108,000
Market Cap
$37.99 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/11/2022
Today
5/18/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.94 out of 5 stars

Medical Sector

659th out of 1,426 stocks

Pharmaceutical Preparations Industry

308th out of 680 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -













Cocrystal Pharma (NASDAQ:COCP) Frequently Asked Questions

Is Cocrystal Pharma a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cocrystal Pharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cocrystal Pharma stock.
View analyst ratings for Cocrystal Pharma
or view top-rated stocks.

Are investors shorting Cocrystal Pharma?

Cocrystal Pharma saw a decline in short interest in April. As of April 30th, there was short interest totaling 139,900 shares, a decline of 23.8% from the April 15th total of 183,600 shares. Based on an average daily volume of 268,600 shares, the short-interest ratio is currently 0.5 days. Currently, 0.2% of the shares of the company are sold short.
View Cocrystal Pharma's Short Interest
.

When is Cocrystal Pharma's next earnings date?

Cocrystal Pharma is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Cocrystal Pharma
.

How were Cocrystal Pharma's earnings last quarter?

Cocrystal Pharma, Inc. (NASDAQ:COCP) released its quarterly earnings results on Wednesday, May, 11th. The company reported ($0.04) earnings per share for the quarter, hitting the consensus estimate of ($0.04).
View Cocrystal Pharma's earnings history
.

What price target have analysts set for COCP?

2 Wall Street analysts have issued twelve-month price objectives for Cocrystal Pharma's shares. Their forecasts range from $4.00 to $5.00. On average, they anticipate Cocrystal Pharma's stock price to reach $4.50 in the next year. This suggests a possible upside of 1,054.4% from the stock's current price.
View analysts' price targets for Cocrystal Pharma
or view top-rated stocks among Wall Street analysts.

Who are Cocrystal Pharma's key executives?
Cocrystal Pharma's management team includes the following people:
  • Dr. Roger D. Kornberg Ph.D., Co-Founder, Chairman, Chief Scientist & Chairman of Scientific Advisory Board (Age 75, Pay $75k)
  • Dr. Sam Lee Ph.D., Co-Founder, Interim Co-CEO & Pres (Age 62, Pay $313k)
  • Mr. James J. Martin CPA, CPA, M.B.A., MBA, Interim Co-CEO, CFO & Corp. Sec. (Age 55, Pay $331k)
What other stocks do shareholders of Cocrystal Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cocrystal Pharma investors own include Moderna (MRNA), Hello Group (MOMO), Intra-Cellular Therapies (ITCI), Impala Platinum (IMPUY), GenMark Diagnostics (GNMK), Gevo (GEVO), Auxly Cannabis Group (CBWTF), Bionano Genomics (BNGO), Blink Charging (BLNK) and Bilibili (BILI).

What is Cocrystal Pharma's stock symbol?

Cocrystal Pharma trades on the NASDAQ under the ticker symbol "COCP."

Who are Cocrystal Pharma's major shareholders?

Cocrystal Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.75%). Company insiders that own Cocrystal Pharma stock include Raymond F Schinazi and Richard C Pfenniger, Jr.
View institutional ownership trends for Cocrystal Pharma
.

Which major investors are selling Cocrystal Pharma stock?

COCP stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Cocrystal Pharma
or view top insider-selling stocks.

How do I buy shares of Cocrystal Pharma?

Shares of COCP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cocrystal Pharma's stock price today?

One share of COCP stock can currently be purchased for approximately $0.39.

How much money does Cocrystal Pharma make?

Cocrystal Pharma has a market capitalization of $37.99 million and generates $2.01 million in revenue each year. The company earns $-14.19 million in net income (profit) each year or ($0.16) on an earnings per share basis.

How many employees does Cocrystal Pharma have?

Cocrystal Pharma employs 13 workers across the globe.

What is Cocrystal Pharma's official website?

The official website for Cocrystal Pharma is www.cocrystalpharma.com.

How can I contact Cocrystal Pharma?

Cocrystal Pharma's mailing address is 19805 N. CREEK PARKWAY, BOTHELL WA, 98011. The company can be reached via phone at (786) 459-1831 or via email at [email protected].

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.